Aesculus Bio ApS Financials, key figures and credit report
Gross profit - 154.9 kDKK FY 2025 -211.1% vs 2024
EBIT - 154.9 kDKK FY 2025 -211.1% vs 2024
Net debt 335.4 kDKK FY 2025 +170.9% vs 2024
Quick ratio 0.3 FY 2025 +0.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 87.68 | -25.02 | -13.63 | -49.79 | - 154.86 |
| EBIT | 87.68 | -25.02 | -13.63 | -49.79 | - 154.86 |
| Other financial income | 0.07 | 0.09 | |||
| Other financial expenses | -0.14 | -1.61 | -0.25 | -9.04 | -11.16 |
| Exchange rate differences | -0.61 | 7.00 | |||
| Pre-tax profit | 86.92 | -19.63 | -13.88 | -58.76 | - 165.94 |
| Income taxes | -13.38 | 5.11 | 3.00 | 12.89 | 36.50 |
| Net earnings | 73.55 | -14.52 | -10.88 | -45.87 | - 129.44 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 203.44 | 203.44 | 203.44 | 203.44 | 203.44 |
| Intangible assets total | 203.44 | 203.44 | 203.44 | 203.44 | 203.44 |
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current other receivables | 3.52 | 1.75 | 45.59 | ||
| Current deferred tax assets | 5.11 | 10.11 | 23.00 | 59.50 | |
| Short term receivables total | 8.63 | 11.86 | 23.00 | 105.09 | |
| Cash and bank deposits | 204.60 | 88.34 | 54.42 | 1.97 | 0.47 |
| Cash and cash equivalents | 204.60 | 88.34 | 54.42 | 1.97 | 0.47 |
| Balance sheet total (assets) | 408.04 | 300.40 | 269.71 | 228.41 | 309.00 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 |
| Share premium account | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| Retained earnings | -26.94 | 46.61 | 32.09 | 21.21 | -24.66 |
| Profit of the financial year | 73.55 | -14.52 | -10.88 | -45.87 | - 129.44 |
| Shareholders equity total | 166.61 | 152.09 | 141.20 | 95.34 | -34.10 |
| Non-current liabilities total | |||||
| Current trade creditors | 28.45 | 17.28 | |||
| Current owed to participating | 116.89 | 116.89 | 116.89 | 125.77 | 335.87 |
| Short-term deferred tax liabilities | 13.38 | ||||
| Other non-interest bearing current liabilities | 82.71 | 14.14 | 11.62 | 7.29 | 7.23 |
| Current liabilities total | 241.43 | 148.32 | 128.51 | 133.06 | 343.09 |
| Balance sheet total (liabilities) | 408.04 | 300.40 | 269.71 | 228.41 | 309.00 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated